Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: I-I or S-I at 0.87 IU daily or placebo were delivered in separate cohorts of diabetic and nondiabetic CD1 mice during 8 months of diabetes. Radiolabeled insulin detection was used to compare delivery and biodistribution for I-I and S-I. Biweekly behavioral testing and monthly electrophysiological and quantitative studies assessed progression of DPN. At and before end point, morphometric analysis of DRG, peripheral nerve, distal epidermal innervation, and specific molecular markers were evaluated. RESULTS: CONCLUSIONS: I-I slows the progression of experimental DPN in streptozotocin mice, avoids adverse effects associated with S-I treatment, and prolongs lifespan when compared with S-I. I-I may be a promising approach for the treatment of DPN.
|
Authors | George Francis, Jose Martinez, Wei Liu, Thuhien Nguyen, Amit Ayer, Jared Fine, Douglas Zochodne, Leah R Hanson, William H Frey 2nd, Cory Toth |
Journal | Diabetes
(Diabetes)
Vol. 58
Issue 4
Pg. 934-45
(Apr 2009)
ISSN: 1939-327X [Electronic] United States |
PMID | 19136650
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Retracted Publication)
|
Chemical References |
- Blood Glucose
- Insulin
- Iodine Radioisotopes
|
Topics |
- Administration, Intranasal
- Animals
- Blood Glucose
(drug effects, metabolism)
- Diabetes Mellitus, Experimental
(drug therapy)
- Diabetic Neuropathies
(drug therapy)
- Hot Temperature
- Injections, Subcutaneous
- Insulin
(administration & dosage, pharmacokinetics, therapeutic use)
- Iodine Radioisotopes
(pharmacokinetics)
- Male
- Mice
- Mice, Inbred Strains
- Nerve Fibers
(drug effects, physiology)
- Reaction Time
(drug effects)
- Tissue Distribution
|